Delivery of Phosphorodiamidate Morpholino Antisense Oligomers in Cancer Cells
Phosphorodiamidate morpholino oligomers (PMO), which have a neutral chemistry, are extensively being used as tools for selective inhibition of gene expression in cell culture models and are currently in human clinical trials. PMO oligomers possess a unique structure, in which the deoxyribose moiety of DNA is replaced with a six-membered morpholine ring and the charged phosphodiester internucleoside linkages are replaced with neutral phosphorodiamidate linkages. PMO internalization in uptake-permissive cells has been observed to be specific, saturable, and energy-dependent, suggesting a receptor-mediated uptake mechanism. Understanding PMO transport should facilitate the design of more effective synthetic antisense oligomers as therapeutic agents.
- PCR of Gene Rearrangements for the Detection of Minimal Residual Disease in Childhood ALL
- Pharmacogenetics of ATP-Binding Cassette Transporters and Clinical Implications
- Generation of Genetically Modified Embryonic Stem Cells for the Development of Knockout Mouse Animal Model Systems
- Animal Models of Prostate Cancer
- Phenotypic and Functional Differences of Dendritic Cells Generated Under Different In Vitro Conditions
- Fluorescence In Situ Hybridization (FISH) to Metaphase and Interphase Chromosomes
- Application of Silicon Sensor Technologies to Tumor Tissue In Vitro: Detection of Metabolic Correlates of Chemosensitivity
- 甲醇酵母表达载体及其元件
- Nonviral Jet-Injection Technology for Intratumoral In Vivo Gene Transfer of Naked DNA
- Analysis of Glycans on Serum Proteins Using Antibody Microarrays